Up­dat­ed: Pfiz­er dis­clos­es pa­tient death in Hym­pa­vzi he­mo­phil­ia tri­al
A pa­tient in Pfiz­er’s tri­al of its he­mo­phil­ia drug Hym­pa­vzi died from a throm­bot­ic stroke, the drug­mak­er said Mon­day.
Pfiz­er said it had in­formed reg­u­la­tors …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
As­traZeneca bets up to B on Ja­co­bio’s pan-KRAS in­hibitor for can­cer
Gala­pa­gos looks for ways to put €3B to use, as last as­set stand­ing posts mixed re­sults
Af­ter year of tri­umph, In­smed stum­bles with chron­ic rhi­nos­i­nusi­tis fail, brings in new as­set
Analyst – Life Sciences Strategy & Intelligence
No­vo Nordisk eyes a strong launch with FDA ap­proval of obe­si­ty pill
Drug­mak­ers with White House MFN deals claim ex­emp­tion from pro­posed Medicare pric­ing tests
Neu­ro­crine’s In­grez­za flunks piv­otal study in dys­k­i­net­ic cere­bral pal­sy
Gilead­'s her­pes deal; FDA ap­provals for Boehringer, Roche
The End­points win­ners and losers list: Who was up and who was down in 2025
Up­dat­ed: Bris­tol My­ers, J&J bring IRA fight to Supreme Court as 'regime of forced sales' is poised to take ef­fect